{
    "id": 4489,
    "name": "malignant epithelial mesothelioma",
    "source": "DOID",
    "definition": null,
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:4489",
    "evidence": [
        
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT02798536",
            "title": "Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6800,
                    "therapyName": "LMB-100",
                    "synonyms": null
                },
                {
                    "id": 6816,
                    "therapyName": "LMB-100 + Nab-paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02810418",
            "title": "Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6800,
                    "therapyName": "LMB-100",
                    "synonyms": null
                },
                {
                    "id": 6816,
                    "therapyName": "LMB-100 + Nab-paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03319537",
            "title": "Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1688,
                    "therapyName": "MLN4924",
                    "synonyms": null
                },
                {
                    "id": 6378,
                    "therapyName": "Cisplatin + MLN4924 + Pemetrexed",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03436732",
            "title": "Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 6802,
                    "therapyName": "LMB-100 + SVP-rapa",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04034238",
            "title": "Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8628,
                    "therapyName": "LMB-100 + Tofacitinib",
                    "synonyms": null
                }
            ]
        }
    ]
}